HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation

被引:139
作者
Ahn, Soomin [1 ]
Woo, Ji Won [1 ,2 ]
Lee, Kyoungyul [3 ]
Park, So Yeon [1 ,2 ]
机构
[1] Seoul Natl Univ, Bundang Hosp, Dept Pathol, 82 Gumi Ro 173beon Gil, Seongnam 13620, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul, South Korea
[3] Kangwon Natl Univ Hosp, Dept Pathol, Chunchon, South Korea
关键词
Breast cancer; HER2; ASCO/CAP guidelines; heterogeneity; CEP17 copy number gain; IN-SITU HYBRIDIZATION; FACTOR RECEPTOR 2; NEOADJUVANT CHEMOTHERAPY; CHROMOSOME-17; POLYSOMY; GENE AMPLIFICATION; AMERICAN-SOCIETY; PROGESTERONE-RECEPTOR; COPY NUMBER; INTRATUMORAL HETEROGENEITY; PROGNOSTIC-SIGNIFICANCE;
D O I
10.4132/jptm.2019.11.03
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is found in about 20% of invasive breast cancers. It is a sole predictive marker for treatment benefits from HER2 targeted therapy and thus, HER2 testing is a routine practice for newly diagnosed breast cancer in pathology. Currently, HER2 immunohistochemistry (IHC) is used for a screening test, and in situ hybridization is used as a confirmation test for HER2 IHC equivocal cases. Since the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines on HER2 testing was first released in 2007, it has been updated to provide clear instructions for HER2 testing and accurate determination of HER2 status in breast cancer. During HER2 interpretation, some pitfalls such as intratumoral HER2 heterogeneity and increase in chromosome enumeration probe 17 signals may lead to inaccurate assessment of HER2 status. Moreover, HER2 status can be altered after neoadjuvant chemotherapy or during metastatic progression, due to biologic or methodologic issues. This review addresses recent updates of ASCO/CAP guidelines and factors complicating in the interpretation of HER2 status in breast cancers.
引用
收藏
页码:34 / 44
页数:11
相关论文
共 81 条
[1]   Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer [J].
Ahn, Soomin ;
Kim, Hyun Jeong ;
Kim, Milim ;
Chung, Yul Ri ;
Kang, Eunyoung ;
Kim, Eun-Kyu ;
Kim, Se Hyun ;
Kim, Yu Jung ;
Kim, Jee Hyun ;
Kim, In Ah ;
Park, So Yeon .
CANCER RESEARCH AND TREATMENT, 2018, 50 (04) :1418-1432
[2]  
[Anonymous], 2007, J CLIN ONCOL, DOI DOI 10.1200/JCO.2006.09.2775
[3]   Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer [J].
Aurilio, Gaetano ;
Monfardini, Lorenzo ;
Rizzo, Stefania ;
Sciandivasci, Angela ;
Preda, Lorenzo ;
Bagnardi, Vincenzo ;
Disalvatore, Davide ;
Pruneri, Giancarlo ;
Munzone, Elisabetta ;
Della Vigna, Paolo ;
Renne, Giuseppe ;
Bellomi, Massimo ;
Curigliano, Giuseppe ;
Goldhirsch, Aron ;
Nole, Franco .
ACTA ONCOLOGICA, 2013, 52 (08) :1649-1656
[4]   Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601) [J].
Bartlett, John M. S. ;
Munro, Alison F. ;
Dunn, Janet A. ;
McConkey, Christopher ;
Jordan, Sarah ;
Twelves, Chris J. ;
Cameron, David A. ;
Thomas, Jeremy ;
Campbell, Fiona M. ;
Rea, Daniel W. ;
Provenzano, Elena ;
Caldas, Carlos ;
Pharaoh, Paul ;
Hiller, Louise ;
Earl, Helena ;
Poole, Christopher J. .
LANCET ONCOLOGY, 2010, 11 (03) :266-274
[5]   Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss [J].
Bogina, Giuseppe ;
Bortesi, Laura ;
Marconi, Marcella ;
Venturini, Marco ;
Lunardi, Gianluigi ;
Coati, Francesca ;
Massocco, Alberto ;
Manfrin, Erminia ;
Pegoraro, Cristina ;
Zamboni, Giuseppe .
VIRCHOWS ARCHIV, 2011, 459 (01) :1-10
[6]   Discordant Human Epidermal Growth Factor Receptor 2 and Hormone Receptor Status in Primary and Metastatic Breast Cancer and Response to Trastuzumab [J].
Chang, Hye Jung ;
Han, Sae-Won ;
Oh, Do-Youn ;
Im, Seock-Ah ;
Jeon, Yoon Kyung ;
Park, In Ae ;
Han, Wonshick ;
Noh, Dong-Young ;
Bang, Yung-Jue ;
Kim, Tae-You .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (05) :593-599
[7]   Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer [J].
Cockburn, Amber ;
Yan, Jingsheng ;
Rahardja, Dewi ;
Euhus, David ;
Peng, Yan ;
Fang, Yisheng ;
Sarode, Venetia Rumnong .
HUMAN PATHOLOGY, 2014, 45 (02) :249-258
[8]   Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma [J].
Couturier, J ;
Vincent-Salomon, A ;
Nicolas, A ;
Beuzeboc, P ;
Mouret, E ;
Zafrani, B ;
Sastre-Garau, X .
MODERN PATHOLOGY, 2000, 13 (11) :1238-1243
[9]   Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis [J].
Curtit, Elsa ;
Nerich, Virginie ;
Mansi, Laura ;
Chaigneau, Loic ;
Cals, Laurent ;
Villanueva, Cristian ;
Bazan, Fernando ;
Montcuquet, Philippe ;
Meneveau, Nathalie ;
Perrin, Sophie ;
Algros, Marie-Paule ;
Pivot, Xavier .
ONCOLOGIST, 2013, 18 (06) :667-674
[10]   Chromogenic in situ hybridization: A novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma [J].
Dandachi, N ;
Dietze, O ;
Hauser-Kronberger, C .
LABORATORY INVESTIGATION, 2002, 82 (08) :1007-1014